Kisqali (ribociclib) - Novartis
Ibrance (palbociclib) - Pfizer
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-induced hepatotoxicity and its resolution: a study of seven cases. (PubMed, Histopathology) - Oct 10, 2026 - "CDK4/6 inhibitor-induced liver injury predominantly manifests as acute hepatocellular injury with zone 3 necrosis and lymphocytic cholangitis. Despite severe histological abnormalities, it resolves with drug withdrawal, and limited cross-reactivity between agents supports individualised therapeutic strategies." 
Journal • Autoimmune Hepatitis • Breast Cancer • Fibrosis • Hepatitis B • Hepatology • Immunology • Liver Failure • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42850905
 
Dupinder Singh; Lisa Centeno; Rifat Mannan; Romil Saxena; Sunayana Misra
 
Oct 10, 2026
 
Prev Next